Great app
Very well designed and seems to work great!
Free
About
Track your symptoms, medication, and lab results for Ankylosing Spondylitis. Visualize pain areas and review your health history through a calendar overview to better communicate with your doctor.
✓Record pain areas visually
✓Track medication intake
✓Log lab results
✓Calendar overview of health history
✓Symptom and medicine logging
Show original description
What's New in Rapha, Ankylosing Spondylitis
2.0
March 6, 2025
Rapha is back with a brand new design. Now you can also add your own custom medicines to track.
User reviews
FAQ
What is Rapha used for?
Rapha is designed to help individuals with Ankylosing Spondylitis easily record and track their symptoms, medication intake, and lab results. It provides a visual way to log pain areas and a calendar overview of your health history.
Does Rapha have ads?
No, Rapha does not contain advertisements, offering an uninterrupted experience for users managing their health.
What devices does Rapha support?
Rapha is currently available for iPhone devices, allowing users to manage their health information on the go.
How often is Rapha updated?
The latest version of Rapha is 2.0, and it was last updated on March 6, 2025. This indicates active development and support for the application.
What is the age rating for Rapha?
Rapha has an age rating of 12+, making it suitable for teenagers and adults managing chronic health conditions.
Can I track my lab results with Rapha?
Yes, Rapha allows you to record and keep track of your lab results within the same app where you log your symptoms and medications, providing a comprehensive health overview.
How does Rapha help me communicate with my doctor?
By visually recording pain areas and providing a calendar overview of your health history, Rapha makes it easier for you to explain your condition and pain levels to your doctor during checkups.
Is there a subscription fee for Rapha?
No, Rapha is available for free and does not require any subscription fees for its core features.
